Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 7Melanoma 5Leukemia 5Colonic Neoplasms 5Rectal Neoplasms 4Leukemia, Myeloid, Acute 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Lymphoma, Follicular 3Fallopian Tube Neoplasms 3Congenital Abnormalities 3Colorectal Neoplasms 3Carcinoma, Ovarian Epithelial 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Ovarian Neoplasms 2Myelodysplastic Syndromes 2Mesothelioma, Malignant 2Lymphoma 2Lung Neoplasms 2Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Leukemia, Eosinophilic, Acute 2Leukemia, Basophilic, Acute 2Head and Neck Neoplasms 2Waldenstrom Macroglobulinemia 1

Interventions

Oxaliplatin 2glucarpidase 1Vincristine 1Pharmacogenomic Testing 1Leucovorin 1Gene Expression Profiling 1Folfox protocol 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neurotoxicity Syndromes × Gene Expression Profiling × Clear all
NCT00884767 2009-07-08

Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin

National Cancer Institute (NCI)

Phase 2 Unknown
206 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡